|
EP4282419A1
(en)
|
2012-12-20 |
2023-11-29 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
EP3974520A1
(en)
|
2013-05-14 |
2022-03-30 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
WO2014190273A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
JP6585041B2
(ja)
|
2013-07-18 |
2019-10-02 |
ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ |
免疫細胞の能力を増強する方法
|
|
US20160333108A1
(en)
*
|
2014-01-13 |
2016-11-17 |
Stephen J. Forman |
CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
|
|
US10189908B2
(en)
|
2014-02-05 |
2019-01-29 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
|
|
CA3190002A1
(en)
*
|
2014-02-14 |
2015-08-20 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
|
US9944709B2
(en)
*
|
2014-03-19 |
2018-04-17 |
Cellectis |
CD123 specific chimeric antigen receptors for cancer immunotherapy
|
|
IL322264A
(en)
*
|
2014-04-07 |
2025-09-01 |
Novartis Ag |
Cancer treatment using chimeric antigen receptor (CAR) against CD19
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
JP6736540B2
(ja)
|
2014-07-21 |
2020-08-05 |
ノバルティス アーゲー |
Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
|
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
US20170209492A1
(en)
*
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
EP3587446A1
(en)
*
|
2014-09-19 |
2020-01-01 |
City of Hope |
Costimulatory chimeric antigen receptor t cells targeting il13 r alpha 2
|
|
KR20170075785A
(ko)
*
|
2014-11-05 |
2017-07-03 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
EP3812398A3
(en)
|
2015-01-23 |
2021-07-21 |
Sanofi |
Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
|
|
EP3250611B1
(en)
|
2015-01-26 |
2021-04-21 |
The University of Chicago |
Car t-cells recognizing cancer-specific il 13r-alpha2
|
|
JP7264592B2
(ja)
|
2015-01-26 |
2023-04-25 |
ザ ユニバーシティー オブ シカゴ |
ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
|
|
WO2016120218A1
(en)
*
|
2015-01-26 |
2016-08-04 |
Cellectis |
ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
CN107530376A
(zh)
|
2015-02-18 |
2018-01-02 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的联合免疫疗法和细胞因子控制疗法
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
WO2016164308A1
(en)
*
|
2015-04-06 |
2016-10-13 |
Subdomain, Llc |
De novo binding domain containing polypeptides and uses thereof
|
|
US10100118B2
(en)
*
|
2015-04-08 |
2018-10-16 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD123
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
IL287500B2
(en)
|
2015-04-21 |
2023-12-01 |
Enlivex Therapeutics Rdo Ltd |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
WO2016180467A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Biontech Cell & Gene Therapies Gmbh |
Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
|
|
EP4190814A1
(en)
|
2015-05-29 |
2023-06-07 |
Amphivena Therapeutics, Inc. |
Methods of using bispecific cd33 and cd3 binding proteins
|
|
CN115927474A
(zh)
|
2015-06-19 |
2023-04-07 |
塞巴斯蒂安·科博尔德 |
Pd-1-cd28融合蛋白及其在医学中的用途
|
|
CN107709356A
(zh)
|
2015-06-26 |
2018-02-16 |
南加利福尼亚大学 |
用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
|
|
AU2016297605A1
(en)
|
2015-07-21 |
2018-02-15 |
City Of Hope |
T cells for expression of chimeric antigen receptors and other receptors
|
|
US10975148B2
(en)
*
|
2015-08-05 |
2021-04-13 |
CellabMED Inc. |
Chimeric antigen receptors, and T cells in which chimeric antigen receptor is expressed
|
|
KR20180053744A
(ko)
*
|
2015-09-23 |
2018-05-23 |
사이토이뮨 테라퓨틱스 엘엘씨 |
면역 요법을 위한 flt3 유도된 car 세포
|
|
US11466097B2
(en)
*
|
2015-10-06 |
2022-10-11 |
City Of Hope |
Chimeric antigen receptors targeted to PSCA
|
|
AU2016337525B2
(en)
|
2015-10-16 |
2022-01-20 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for inhibition of lineage specific antigens
|
|
JP7018387B2
(ja)
|
2015-10-16 |
2022-02-10 |
ルードヴィッヒ－マクシミリアン－ユニヴェルシタート ミュンヘン |
腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞
|
|
CN116059316A
(zh)
|
2015-10-23 |
2023-05-05 |
优瑞科生物技术公司 |
抗体/t细胞受体嵌合构建体及其用途
|
|
EP3368075B1
(en)
|
2015-10-27 |
2020-01-29 |
Board of Regents, The University of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
|
CN108779174B
(zh)
*
|
2015-11-04 |
2022-11-29 |
希望之城公司 |
靶向her2的嵌合抗原受体
|
|
CN108884140B
(zh)
|
2015-12-03 |
2022-10-25 |
朱诺治疗学股份有限公司 |
修饰的嵌合受体及相关组合物和方法
|
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
|
BR112018013074A2
(en)
|
2015-12-30 |
2018-12-11 |
Novartis Ag |
immune effector cell therapies with enhanced efficacy
|
|
CA3014885A1
(en)
|
2016-02-18 |
2017-08-24 |
Enlivex Therapeutics Ltd. |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
WO2017172981A2
(en)
*
|
2016-03-29 |
2017-10-05 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
US12144850B2
(en)
|
2016-04-08 |
2024-11-19 |
Purdue Research Foundation |
Methods and compositions for car T cell therapy
|
|
EP3443096B1
(en)
|
2016-04-15 |
2023-03-01 |
Novartis AG |
Compositions and methods for selective expression of chimeric antigen receptors
|
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
|
AU2017291262A1
(en)
|
2016-06-30 |
2019-01-03 |
F. Hoffmann-La Roche Ag |
Improved adoptive T-cell therapy
|
|
EP3490590A2
(en)
|
2016-08-01 |
2019-06-05 |
Novartis AG |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
CN107793481A
(zh)
*
|
2016-08-31 |
2018-03-13 |
南京传奇生物科技有限公司 |
一种靶向人cd123的嵌合受体配体及其应用
|
|
CN107840889A
(zh)
*
|
2016-09-19 |
2018-03-27 |
上海吉倍生物技术有限公司 |
高亲和力的抗cd123抗体及其应用
|
|
PL3532497T3
(pl)
|
2016-10-26 |
2024-11-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji
|
|
IL317416A
(en)
*
|
2016-11-16 |
2025-02-01 |
Ablynx Nv |
T cell-recruiting polypeptides capable of binding CD123 and TCR alpha/beta
|
|
US20200095547A1
(en)
|
2016-12-02 |
2020-03-26 |
Darya ALIZADEH |
Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
AU2018219226B2
(en)
|
2017-02-07 |
2024-12-19 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
WO2018176159A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Zymeworks Inc. |
Tumor antigen presentation inducer constructs and uses thereof
|
|
US11344578B2
(en)
|
2017-04-19 |
2022-05-31 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
AU2018258045B2
(en)
|
2017-04-26 |
2024-02-29 |
Eureka Therapeutics, Inc. |
Chimeric antibody/T-cell receptor constructs and uses thereof
|
|
WO2019103857A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
EP3650539A4
(en)
*
|
2017-07-07 |
2021-08-18 |
Hanmi Pharm. Co., Ltd. |
NEW THERAPEUTIC ENZYMFUSION PROTEIN AND ITS USAGE
|
|
CN111148533A
(zh)
|
2017-09-19 |
2020-05-12 |
麻省理工学院 |
用于嵌合抗原受体t细胞疗法的组合物及其用途
|
|
KR20200086278A
(ko)
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
CN107759700A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd19抗原的转基因t细胞及其制备方法与应用
|
|
WO2019084288A1
(en)
*
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS
|
|
EP3707165A4
(en)
*
|
2017-11-07 |
2021-09-08 |
The Board of Regents of The University of Texas System |
LILRB4 TARGETING WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER
|
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
WO2019099440A1
(en)
|
2017-11-14 |
2019-05-23 |
Arcellx, Inc. |
Multifunctional immune cell therapies
|
|
BR112020009136A2
(pt)
|
2017-11-14 |
2020-10-13 |
Arcellx, Inc. |
polipeptídeos que contêm domínio d e usos dos mesmos
|
|
GB201719646D0
(en)
*
|
2017-11-27 |
2018-01-10 |
Bivictrix Therapeutics Ltd |
Therapy
|
|
US11311576B2
(en)
|
2018-01-22 |
2022-04-26 |
Seattle Children's Hospital |
Methods of use for CAR T cells
|
|
CN108276495B
(zh)
*
|
2018-01-24 |
2022-03-18 |
博生吉医药科技(苏州)有限公司 |
靶向csf1r嵌合抗原受体修饰的nk92mi细胞和t细胞及其制法和应用
|
|
WO2019156795A1
(en)
|
2018-02-06 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
CA3091674A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
CN111918877A
(zh)
|
2018-03-14 |
2020-11-10 |
美国卫生和人力服务部 |
抗cd33嵌合抗原受体及其用途
|
|
WO2019195583A1
(en)
*
|
2018-04-06 |
2019-10-10 |
Mustang Bio, Inc. |
Manufacturing methods for cell-based therapeutic compositions
|
|
EP3773632A4
(en)
|
2018-04-06 |
2022-05-18 |
The Regents of The University of California |
METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMA
|
|
CA3095757A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating glioblastomas
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
AU2019284911B2
(en)
|
2018-06-13 |
2026-04-09 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
US20210268028A1
(en)
*
|
2018-07-02 |
2021-09-02 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
|
EP3820484A4
(en)
|
2018-07-10 |
2022-05-04 |
Precigen, Inc. |
ROR-1 SPECIFIC CHIMERA ANTIGEN RECEPTORS AND USES THEREOF
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
AU2019346335B2
(en)
|
2018-09-28 |
2024-07-25 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
EP3873540A4
(en)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
CA3116412A1
(en)
|
2018-10-31 |
2020-05-07 |
Humanigen, Inc. |
Materials and methods for treating cancer
|
|
WO2020092839A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
WO2020113054A1
(en)
*
|
2018-11-30 |
2020-06-04 |
Mustang Bio, Inc. |
Methods of treatment using decitabine and a cd123-targeted therapy
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
BR112021015672A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3927738A1
(en)
|
2019-02-20 |
2021-12-29 |
City of Hope |
Baff-r/cd19 targeted chimeric antigen receptor-modified t cells and use thereof
|
|
KR20210136050A
(ko)
|
2019-03-01 |
2021-11-16 |
이오반스 바이오테라퓨틱스, 인크. |
액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
|
|
US20220143087A1
(en)
|
2019-03-08 |
2022-05-12 |
Klinikum Der Universitat Munchen |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
|
WO2020205751A1
(en)
|
2019-03-29 |
2020-10-08 |
City Of Hope |
Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
EP3769816A1
(en)
*
|
2019-07-25 |
2021-01-27 |
Ospedale Pediatrico Bambino Gesù |
Car-cd123 vector and uses thereof
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
CN110904048A
(zh)
*
|
2019-12-04 |
2020-03-24 |
合肥中科干细胞再生医学有限公司 |
一种car-cd123t2嵌合抗原受体t细胞及其应用
|
|
JP2023506501A
(ja)
*
|
2019-12-16 |
2023-02-16 |
ワシントン・ユニバーシティ |
キメラ抗原受容体樹状細胞（ｃａｒ－ｄｃ）ならびにこれを作製および使用する方法
|
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
|
KR20220163940A
(ko)
|
2020-02-04 |
2022-12-12 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
항-디니트로페놀 키메라 항원 수용체
|
|
CA3173527A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
CN113493772B
(zh)
*
|
2020-04-08 |
2022-10-18 |
华中农业大学 |
可分泌性表达免疫毒素的嵌合抗原受体修饰的免疫细胞
|
|
US12264190B2
(en)
*
|
2020-04-24 |
2025-04-01 |
Astrazeneca Ab |
Compositions and methods of treating cancer with chimeric antigen receptors
|
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
CN116096862A
(zh)
|
2020-06-11 |
2023-05-09 |
诺华股份有限公司 |
Zbtb32抑制剂及其用途
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN112079927B
(zh)
*
|
2020-09-18 |
2021-12-28 |
西安桑尼赛尔生物医药有限公司 |
一种cd123结合蛋白、含其的car及其应用
|
|
CN112521505B
(zh)
*
|
2020-12-11 |
2022-07-29 |
华道(上海)生物医药有限公司 |
抗cd123抗体及其应用
|
|
CN112646033B
(zh)
*
|
2020-12-16 |
2022-04-12 |
北京艺妙神州医药科技有限公司 |
靶向cd123的嵌合抗原受体及其用途
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
EP4387991A1
(en)
|
2021-08-18 |
2024-06-26 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
|
US20260083848A1
(en)
|
2021-11-03 |
2026-03-26 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
AU2023205629A1
(en)
|
2022-01-05 |
2024-08-15 |
Fundació De Recerca Clinic Barcelona-Institut D’Investigacions Biomèdiques August Pi I Sunyer |
Anti-cd84 antibodies and chimeric antigen receptors
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2024094004A1
(zh)
*
|
2022-11-03 |
2024-05-10 |
重庆精准生物技术有限公司 |
靶向cd123的全人源抗体及其应用
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2024123835A1
(en)
|
2022-12-06 |
2024-06-13 |
Dynamic Cell Therapies, Inc. |
Engineered switches for immune cell activity and methods of use thereof
|
|
EP4630043A1
(en)
|
2022-12-06 |
2025-10-15 |
Dynamic Cell Therapies, Inc. |
Immune-activating complexes
|
|
EP4720059A1
(en)
|
2023-05-24 |
2026-04-08 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
CN117430721B
(zh)
*
|
2023-10-25 |
2024-06-25 |
北京景达生物科技有限公司 |
Cd123靶向car-nk细胞的制备及其应用
|
|
EP4599843A1
(en)
|
2024-02-09 |
2025-08-13 |
Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau |
Car and modified cd200r combination
|
|
WO2025255266A1
(en)
|
2024-06-05 |
2025-12-11 |
Dynamic Cell Therapies, Inc. |
Engineered polypeptides for immune cell activation
|